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ABSTRACT 
 
Background & objectives: Clinical laboratories need to develop 
quick screening methods for detection of Extended Spectrum β-
Lactamases (ESBL) & Amplified C (AmpC) β-Lactamase, so that 
the appropriate medication can be started without delay. Here, 
we reported the screening & confirmatory methods for detection 
of ESBL & AmpC in Klebsiella pneumoniae in Neonatal Intensive 
Care Unit (NICU).  
Methods: We had tested 600 blood culture samples from the 
NICU patients. From the positive bacterial isolates, Klebsiella 
pneumoniae were screened for ESBL & AmpC production 
followed by confirmatory methods as per Clinical Laboratory 
Standard Institute (CLSI) guidelines.  
Results: Out of the 600 blood culture, 266 were positive for 
microbial growth. Among them, Klebsiella pneumoniae were in 
54 patients. Out of 54 Klebsiella pneumoniae, 48 were positive for 
ESBL in screening method. Out of 48, 41 isolates were ESBL 
positive & 4 were AmpC positive by Confirmatory test (Modified 
Three Dimensional Method for AmpC).  
Interpretation & conclusions: The prevalence of ESBL & AmpC 
producing Klebsiella pneumoniae in NICU at our institute is 
75.92% & 7.4% which is very alarming, and it requires strict 
implementation of infection control guidelines in NICU by safe 
hygiene practices, restricted use of broad spectrum antibiotics as 
empirical therapy in septicemic cases and also formulation of 
uniform antibiotic policy for such patients based on the current 
trend of antibiotic resistance. This can be helpful in preventing 
emergence of multidrug resistance in such organisms. 
 
Key words: ESBL, AmpC, Klebsiella pneumoniae, Neonatal 
septicemia. 
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INTRODUCTION 
Septicaemia is one of the leading causes of 
neonatal mortality along with perinatal hypoxia. 
The most common organisms responsible for 
these infections are multidrug resistant gram 
negative bacilli particularly members of the 
family  Enterobacteriaceae. 1 Several outbreaks of 
septicaemia by gram negative isolates have been 
reported and phenomenon of isolation of ESBLs 
producing isolates is not uncommon and is 
associated with increased mortality.1 
Extended spectrum Β- lactamases (ESBLs) are 
plasmid mediated, TEM and SHV derived 
enzymes, first isolated in Western Europe in mid 
1980s, most commonly in Klebsiella  spp., 
followed by Escherichia coli. These enzymes are 
capable of hydrolyzing broad spectrum 
cephalosporins, penicillins and monobactams 
such as aztreonam, but inactive against 
cephamycins and imipenem & are usually 
inhibited by β-Lactamase inhibitors such as 
clavulanic acid. In addition, Plasmids 
responsible for ESBL production tend to be large 
(80 Kb or more in size) and carry resistance to 
several agents, an important limitation in the 
design of treatment alternatives. The most 
frequent co-resistances found in ESBL 
producing organisms are aminoglycosides, 
fluoroquinolones, tetracyclines, 
chloramphenicol and sulfamethoxazole-
trimethoprim resulting in limitation of 
therapeutic option. 2  Furthermore, due to the 
variable affinity of these enzymes for different 
substrates and inoculum effect, some ESBL 
isolates may appear susceptible to a third 
generation cephalosporin in vitro. However, 
treatment of infections due to an ESBL 
producing organism with third generation 
cephalosporins may result in clinical failure.2 
AmpC β- lactamases are cephalosporinases that 
are poorly inhibited by clavulanic acid & can be 
differentiated from ESBLs by their ability to 
hydrolyse cephamycins. Now a day, Klebsiella 
pneumoniae is also found to produce AmpC β-
Lactamases. The increased prevalence of 
bacterial pathogens producing both ESBLs & 
AmpC β-Lactamases creates requirement for the 
laboratory testing methods that can accurately 
detect the presence of these enzymes in clinical 
laboratories.3 
The study was conducted to know prevalence of 
ESBL & AmpC production in Klebsiella 
pneumoniae in NICU. We also studied antibiotic 
sensitivity pattern of ESBL producing isolates of 
Klebsiella pneumoniae s o  t h a t  w e  c a n  h e l p  
clinicians to avoid injudicious use of antibiotics 
and giving susceptible antimicrobials to prevent 
therapeutic failure in neonates having infection 
with ESBL positive Klebsiella pneumoniae. 
 
MATERIALS & METHODS 
The present study was carried out from 
February 2009 to July 2009 in Microbiology 
Department of Tertiary Care Medical Centre 
affiliated with Medical College in Western India. 
A total of 600 samples of blood culture from 
neonates admitted in the NICU were processed 
for the study. 
After taking universal precautions, blood for the 
culture was collected aseptically. Two ml blood 
was collected in brain heart infusion broth 
prepared for paediatric use.  Blood culture 
bottles were sent immediately to the 
Microbiology laboratory.4,5 In the laboratory, 
blood culture samples were processed by the 
standard methods. Klebsiella pneumoniae were 
stamped by their colony morphology & 
standard biochemical reactions. 5 
As per the CLSI (Clinical Laboratory Standards 
Institute) guidelines, antibiotic susceptibility 
testing was performed by Kirby-Bauer method. 
Quality Control strains, E.coli ATCC 25922 (β-
Lactamase negative) and Klebsiella pneumoniae 
ATCC 700603 (ESBL positive) were used. 6 
 
Screening test for ESBL detection: 
Screening for ESBL was done according to the 
CLSI guidelines. All Klebsiella pneumoniae 
isolates were screened for ESBL production by 
Kirby-Bauer’s disc diffusion method, 
demonstrating reduced susceptibility to 
cefpodoxime (30 μg), cefotaxime (30μg), 
ceftazidime (30 μg), ceftriaxone(30 μg) and 
aztreonam (30 μg). Cut-off zone sizes as an 
indicator of ESBL producer were ≤ 27 mm for 
cefotaxime, ≤ 22 mm for ceftazidime, ≤ 25 mm 
for ceftriaxone, ≤ 27 mm for aztreonam and ≤ 17 
mm for cefpodoxime. 6 
 
Confirmatory Test for ESBL Detection: 
Phenotypic Confirmatory Disc Diffusion Test 
(PCDDT): 
This was done by placing a disk of ceftazidime 
(30 μg) alone and ceftazidime + clavualanic acid 
(30/10  μg) on a Mueller-Hinton Agar plate at  
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least 20 mm apart from each other. After 
overnight incubation plates were examined. The 
zone diameter around ceftazidime + clavualanic 
acid disc ≥ 5mm larger than that around 
ceftazidime disk was indicated as ESBL 
production. 6 
 
Screening Test for AmpC β-lactamases: 
An isolate was screened for AmpC β-
Lactamases by Kirby-Bauer’s disc diffusion 
method demonstrating reduced susceptibility to 
cefoxitin (30 μg) as ≤18mm zone of inhibition.7 
 
Confirmatory Test for AmpC β-lactamase: 
Modified Three-Dimensional Test (MTDT): 
The isolates showing positive screening test 
result by cefoxitin disc diffusion test was 
confirmed by MTDT.  Briefly, fresh overnight 
growth from Mueller Hinton Agar was 
transferred to a pre-weighed sterile micro-
centrifuge tube. The tube was weighed again to 
determine the weight of bacterial mass to obtain 
10-15 mg of bacterial wet weight. The bacterial 
mass was suspended in peptone water and 
pelleted by centrifugation at 3000 rpm for 15 
minutes. Crude enzyme extract was prepared by 
freezing and thawing the bacterial pellet (five 
cycles).  
Lawn culture of E. coli ATCC 25922 was 
prepared on Mueller Hinton Agar plates, and a 
cefoxitin (30 μg) disc was placed on the surface 
of the medium. Linear slits (3 cm long) were cut 
using sterile surgical blade up to a point 3 mm 
away from the edge of the cefoxitin disc. Wells 
of 8 mm diameter were made on the slits at a 
distance 5 mm inside from the outer end of the 
slit using a sterile pasteur pipette. The wells 
were loaded with enzyme extract in 10 μl 
increments until the well was full. 
Approximately 30-40 μl of extract was loaded in 
a well.  
The plates were incubated at 37 °C for 
overnight. Three different kinds of results were 
recorded. Isolates that showed clear distortion of 
zone of inhibition of cefoxitin were taken as 
AmpC producers. Isolates with no distortion 
were taken as AmpC non-producers.7,8 
 
RESULTS & OBSERVATIONS 
In this study, total of 600 blood culture samples 
from NICU patients suspected of having 
septicemia were processed for the detection of 
Klebsiella pneumoniae with ESBL & AmpC 
production. 
Out of 600 cases, growth was obtained in 266 
patients. Among them, 256 were positive for 
bacteria & 10 for candida spp.(figure-1) 
 
 
Figure:1 Incidence of Neonatal septicemia in 
neonatal intensive cae unit 
 
Klebsiella spp. were isolated in 63 isolates out of 
total 256 bacterial isolates.(Table-1) Out of total 
63 Klebsiella species, Klebsiella pneumoniae were 54, 
while  Klebsiella oxytoca were 6 & Klebsiella 
ornitholytica were 3 in number. 
 
Table 1: Bacteriological profile of neonatal 
septicemia 
Organism isolated from neonatal 
septicaemia 
Positive  
isolates(%) 
Staphylococcus coagulase negative  73  (27.44) 
Klebsiella species  63  (23.68) 
Pseudomonas aeruginosa  42  (15.78) 
Acinetobacter species  37  (13.90) 
E. coli  26  (9.77) 
Candida species  10  (3.75) 
Staphylococcus aureus  08  (3.00) 
Streptococcus species  03  (1.12) 
Proteus vulgaris  01  (0.37) 
Morganella species  01  (0.37) 
Enterococus species  01  (0.37) 
Total 266  (100) 
 
In screening test, out of 54 Klebsiella pneumoniae, 
48 the Klebsiella pneumoniae species had exhibited 
resistance to at least any one of the five indicator 
antibiotics (cefotaxime, ceftazidime, 
cefpodoxime, ceftriaxone & aztreonam) & 4 had 
exhibited resistance to cefoxitin. So, 48 isolates 
Bacterial growth 
(256) 
Fungal growth 
(10) 
Positive blood 
culture 
Gram negative 
Bacilli (170)  
(63.90%) 
Gram positive 
Cocci (86) 
(32.33%) 
Candida 
spp. 
(10) (3.75%)   
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respectively.1,11 But in most of the studies 
Klebsiella pneumoniae was seen as predominating 
bacterial isolate responsible for fatal septicaemia 
in neonates. 
As report of blood culture isolation and 
antibiotic susceptibility results are usually 
available after 72 hours or more, any delay in 
the initiation of correct empirical therapy or 
improper choice of antimicrobials cannot be 
justified. It is a common practice to use 
ampicillin and an aminoglycoside or a third 
generation cephalosporin in neonatal 
septicaemic cases.1 Wide spread use of third 
generation cephalosporins and aztreonam is 
believed to be the major cause of the mutations 
in TEM and SHV enzymes that has led to the 
emergence of the ESBLs. 
ESBL screening method recommended by CLSI 
for E.coli & Klebsiella species had identified that 
48 isolates of Klebsiella pneumoniae out of 54 
showed decreased susceptibility to at least any 
one indicator for ESBL detection. Thus in our 
study 88.88% Klebsiella pneumoniae were screen 
positive for ESBL detection test by CLSI criteria, 
while one study done by A. Bhattacharjee at 
Varanasi had recorded that 100%1  Klebsiella 
pneumoniae were screened positive for ESBL 
detection test. ESBL production was confirmed 
by Phenotypic confirmatory disk diffusion 
method recommended by CLSI in 41 isolates. So 
the prevalence of ESBL producing Klebsiella 
pneumoniae in our Neonatal ICU was 75.92%. 
Brendan et al, Amita Jain et al, Bhattacharjee et 
al & I Roy et al had shown the prevalence of 
ESBL producing Klebsiella pneumoniae as 25%, 
58%, 62.50% & 86.60% respectively.13,12,1,10 Major 
risk factors for colonization or infection with 
ESBL producing organisms are long term 
antibiotic exposure, prolonged ICU stay, 
nursing home residency, severe illness, 
residence in an institution with high rates of 
third generation cephalosporin use and 
instrumentation or catheterisation.2 Our institute 
is the tertiary care medical center, so we have 
patients mainly referred from PHCs, CHCs and 
in addition also from private sectors due to 
complicated life threatening infections. This 
leads to use of higher antibiotics by the 
clinicians as a common empirical therapy 
without waiting for the susceptibility results. In 
addition, due to heavy patients load, proper 
infection control measures can not be 
maintained by the paramedical staff. Majority of 
the time, Intensive care units are occupied with 
the patients. So, proper fumigation of the ICUs 
at regular interval is not possible. Also, the 
neonates having low birth weight or deficient 
immune response are more prone to the 
infections by the nursing staff or other medical 
staff if proper hygiene is not maintained while 
handling them in NICUs. In such cases, 
neonates are suffering from nosocomial 
infections caused by multidrug resistant 
organisms which are easily spreading in nature. 
All of these factors lead to the higher rate of 
ESBL and AmpC β-Lactamse producing 
organisms in our institute. 
Antibiotic susceptibility pattern of ESBL positive 
isolates showed that all 2nd generation 
cephalosporins, 3rd generation cephalosporins 
and aztreonam were resistant. The cefepime was 
resistant in three isolates. The imipenem was 
sensitive in all ESBL producing isolates. 
Amoxiclav was sensitive in 41 cases while 
Piperacillin- tazobactam was sensitive in 32 
cases. Co-resistance to other group of drugs was 
noted in ESBL producing organisms. In addition 
to imipenem, good activity against ESBL 
producing  Klebsiella pneumoniae was noted by 
amikacin & moxifloxacin. Amikacin was 
sensitive in 29 cases while moxifloxacin was 
sensitive in 39 cases. So depending on the 
sensitivity pattern, these drugs can be given to 
the serious neonatal septicemic patient. 
Amikacin and higher quinolones are good 
alternatives and they will also provide some 
economic relief to the patients. Imipenem drug 
should be reserved for the future resource. 
Continued monitoring of the susceptibility 
pattern of the organisms is necessary in clinical 
settings to detect true burden of the antibiotic 
resistance for proper disease management. 
 
CONCLUSION 
Our institute which is tertiary care center of 
Gujarat (India) has a high prevalence of 
nosocomial infections in NICU due to Klebsiella 
pneumoniae.Thus incidence of Neonatal 
septicaemia in our study is 44.33% (266/600). 
The prevalence of Klebsiella pneumoniae in NICU 
patients is 20.30%(54/266). The prevalence of 
ESBL & AmpC producing Klebsiella pneumoniae 
in NICU at our institute is 75.92% & 7.4%. The 
higher prevalence rate of ESBL and AmpC 
producing organisms shows that in the future, 
problems in treatment of serious infections by 
MDR (Multi Drug Resistant) organism will be 
increasing. This result warns us to prevent intra 
– institutional spread of these organisms by  
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limiting the use of these agents alone or in 
combination with infection control measures. 
Educational programs for medical staff to 
increase awareness should also be developed. 
Antibiotic policy should be formulated for 
empirical therapy in high risk intensive care 
units where infections due to resistant 
organisms are much higher. 
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